Younis J S
Department of Obstetrics and Gynecology, Bar-Ilan University, Israel.
Minerva Endocrinol. 2012 Mar;37(1):41-57.
Ovarian aging is a major detrimental factor of pregnancy achievement and it is related to other issues of women's health. The purpose of this review is to present an update on ovarian aging risk factors followed by contemporary methods of its assessment and an overview of its current management strategies in assisted reproductive technologies (ART). Ovarian aging is a multifactorial trait governed by several factors including medical, lifestyle, genetic, autoimmune and idiopathic. There are several established risk factors and many others that are still being revealed. Heritability has a major influence on ovarian aging. Different genetic strategies and approaches for ovarian aging evaluation have been rapidly expanding; however the mission is far from complete. Genome-wide association studies seems to be the most applicable to advance this research. Although anti-Müllerian hormone and antral follicle count (AFC) biomarkers seems to be the most reliable predictors of ovarian aging, none has demonstrated conclusive evidence to predict pregnancy achievement in an ART setting. The debate continues which of the two predictors is the most suitable in ART as well as non-ART settings. Although multivariate models have been shown to be equally predictive to AFC, latest data support the notion that chronological age and genetic markers inclusion may increase their reliability. Several strategies have been suggested to manage ovarian aging in ART settings. None of the stimulation protocols or ART interventions has been shown to be convincingly beneficial to ovarian aging women and individualization of treatment is still recommended. Ovarian priming by different androgen preparations has been shown to be promising but more randomized controlled studies are required to substantiate these findings. Except for oocyte donation other ART strategies have not shown a persuasive evidence for advanced ovarian aging infertility patients. The new development of oocyte vitrification may well introduce opportunities for fertility preservation to woman at risk. It is concluded that proper assessment and detection of ovarian aging, employing current or developing biomarkers of ovarian reserve, may enable health providers to recommend, at appropriate biological time, early pregnancy achievement or fertility preservation in women at risk.
卵巢衰老 是影响受孕的一个主要不利因素,并且与女性健康的其他问题相关。本综述的目的是介绍卵巢衰老风险因素的最新情况,接着阐述其当代评估方法,并概述辅助生殖技术(ART)中目前针对卵巢衰老的管理策略。卵巢衰老 是一种多因素特征,受多种因素影响,包括医学因素、生活方式、遗传因素、自身免疫因素和特发性因素。目前已有多种确定的风险因素,还有许多其他因素仍在不断被揭示。遗传力对卵巢衰老有重大影响。评估卵巢衰老的不同遗传策略和方法一直在迅速扩展;然而,这项任务远未完成。全基因组关联研究似乎最适用于推进这项研究。尽管抗苗勒管激素和窦卵泡计数(AFC)生物标志物似乎是卵巢衰老最可靠的预测指标,但在辅助生殖技术环境中,尚无一项能确凿证明可预测受孕情况。关于这两种预测指标在辅助生殖技术以及非辅助生殖技术环境中哪一种最合适的争论仍在继续。尽管多变量模型已被证明与AFC具有同等预测性,但最新数据支持这样一种观点,即纳入实际年龄和遗传标志物可能会提高其可靠性。在辅助生殖技术环境中,已提出多种管理卵巢衰老的策略。没有一种刺激方案或辅助生殖技术干预措施已被证明对卵巢衰老女性有令人信服的益处,因此仍建议进行个体化治疗。不同雄激素制剂进行卵巢预处理已显示出前景,但需要更多随机对照研究来证实这些结果。除了卵母细胞捐赠外,其他辅助生殖技术策略尚未为卵巢严重衰老的不孕患者提供有说服力的证据。卵母细胞玻璃化冷冻的新进展很可能为有风险的女性带来生育力保存的机会。结论是,通过采用当前或正在开发的卵巢储备生物标志物,对卵巢衰老进行适当评估和检测,可能使医疗服务提供者能够在适当的生理时机,为有风险的女性推荐早期受孕或生育力保存措施。